Aanem Presents Nerve And Muscle Junction

Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis, Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) Trials

Informações:

Sinopse

Dr. Elie Naddaf, MD interviews Dr. James Howard, MD about the use of complement and the neonatal Fc receptor inhibitors in myasthenia gravis, highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials.